Population Pharmacokinetic Analysis of Itacitinib, a Selective JAK-1 Inhibitor
Sign Up to like & getrecommendations! Published in 2019 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2018.12.256
Abstract: Statement of Purpose, Innovation, or Hypothesis Itacitinib is a JAK-1 inhibitor currently in phase III development for the treatment of acute and chronic graft versus host disease (GVHD) in combination with corticosteroids. Itacitinib is primarily… read more here.
Keywords: pharmacokinetic analysis; population; itacitinib; population pharmacokinetic ... See more keywords
Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of pharmacology"
DOI: 10.1016/j.ejphar.2020.173505
Abstract: Pharmacological modulation of the Janus kinase (JAK) family has achieved clinically meaningful therapeutic outcomes for the treatment of inflammatory and hematopoietic diseases. Several JAK1 selective compounds are being investigated clinically to determine their anti-inflammatory potential.… read more here.
Keywords: inhibitor; treatment inflammatory; itacitinib; disease ... See more keywords